Roche: EU drug panel recommends approval of Phesgo
(CercleFinance.com) - A panel of the European medicines regulator has recommended approving Roche's Phesgo for the treatment of HER2-positive breast cancer, the Swiss drugmaker said on Friday.
The European Medicines Agency's human medicines committee (CHMP) has adopted a positive opinion on this combination of Roche's two best-selling cancer drugs - Perjeta and Herceptin -, which offers faster and less invasive sub-cutaneous delivery.
The subcutaneous administration of Phesgo takes approximately eight minutes, compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using standard intraveinous formulations, Roche said.
The European Commission generally follows CHMP's recommendations in a matter of months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The European Medicines Agency's human medicines committee (CHMP) has adopted a positive opinion on this combination of Roche's two best-selling cancer drugs - Perjeta and Herceptin -, which offers faster and less invasive sub-cutaneous delivery.
The subcutaneous administration of Phesgo takes approximately eight minutes, compared to approximately 150 minutes for infusion of a loading dose of Perjeta and Herceptin using standard intraveinous formulations, Roche said.
The European Commission generally follows CHMP's recommendations in a matter of months.
Copyright (c) 2020 CercleFinance.com. All rights reserved.